Aura Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Aura Biosciences, Inc. (AURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.40% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.40%, a 7.58% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.72%, a 15.07% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.90%, a 0.26% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.09%, a 6.41% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.26%, a 8.40% increase from fiscal 2024.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.93%, a 0.25% decline from fiscal 2023.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.94%, a 31.33% increase from fiscal 2022.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.00%, a 160.87% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.40% 10-Q · filed 2026-08-11 | 4.12% 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 3.72% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 4.26% 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-13 | 4.29% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 4.09% 10-Q · filed 2026-08-11 | 4.31% 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | 4.38% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 3.93% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 3.89% 10-Q · filed 2025-11-13 | 3.93% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 4.37% 10-Q · filed 2025-08-13 | 3.93% 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | 3.84% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 3.94% 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 4.22% 10-Q · filed 2024-11-12 | 3.68% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 3.69% 10-Q · filed 2024-08-08 | 3.57% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 3.53% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 3.00% 10-K · filed 2024-03-27 | |||
| 2022-09-30 | 3.08% 10-Q · filed 2023-11-09 | 2.73% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 3.09% 10-Q · filed 2023-08-09 | 2.53% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 1.56% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 1.15% 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-10 | 1.06% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 1.07% 10-Q · filed 2022-08-11 | 1.07% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 1.02% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.55% 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 0.33% 10-Q · filed 2021-11-24 | 0.58% 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |